17 completed, 5 withdrawn, 4 terminated, 1 recruiting. 16 Phase 2, 7 Phase 1, 6 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 9, Terminated 3, Withdrawn 3, Recruiting 1 |
| Phase 1 | 7 | Withdrawn 3, Completed 2, Recruiting 1, Terminated 1 |
| Not applicable | 6 | Completed 5, Withdrawn 1 |
Follow HonorHealth Research Institute: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma Tegavivint - Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | HonorHealth Research Institute | 126 | 2026-02-17 | 2026-03-11 |
| Internet-delivered Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) Internet delivered pain coping skills training - CIPN - Chemotherapy-Induced Peripheral Neuropathy | Not applicable | Withdrawn | Wake Forest University Health Sciences | 2025-02-01 | 2025-04-06 | |
| The Seven Trial: Exploiting the Unfolded Protein Response Botensilimab, Balstilimab, Chloroquine Phosphate - Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic | Phase 1 | Terminated | HonorHealth Research Institute | 6 | 2025-01-09 | 2026-06-23 |
| Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas Pemigatinib 4.5 MG - Pancreas Cancer | Phase 2 | Withdrawn | HonorHealth Research Institute | 2022-06-14 | 2023-07-03 | |
| Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations Lurbinectedin 4 MG Injection [Zepzelca] - Gastrointestinal Malignancies | Phase 2 | Completed | HonorHealth Research Institute | 8 | 2022-06-14 | 2026-09-11 |
| Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Novocure Optune, Opdivo, Yervoy - Uveal Melanoma | Phase 1 | Completed | HonorHealth Research Institute | 10 | 2022-02-28 | 2025-08-15 |
| Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers SP-2577, Pembrolizumab - SCCOHT, Ovarian Clear Cell Tumor | Phase 1 | Withdrawn | HonorHealth Research Institute | 2021-12-31 | 2022-03-02 | |
| Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine Eucalyptus Oil Scent, Isopropyl Alcohol Vapors - Migraine | Not applicable | Completed | HonorHealth Research Institute | 21 | 2021-11-11 | 2026-04-17 |
| Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer Vemurafenib, Sorafenib - Pancreas Cancer | Phase 2 | Completed | HonorHealth Research Institute | 10 | 2021-10-28 | 2026-03-30 |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer Paclitaxel protein bound, Gemcitabine, Cisplatin - Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 19 | 2020-12-01 | 2026-07-21 |
| Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection Atovaquone/Azithromycin - Covid19 | Phase 2 | Terminated | HonorHealth Research Institute | 3 | 2020-04-20 | 2026-06-29 |
| The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention - Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant | Not applicable | Completed | Arizona State University | 18 | 2020-02-04 | 2022-05-23 |
| Hair Loss Prevention Study for Pancreatic Cancer Paxman Scalp Cooling Device - Alopecia | Not applicable | Completed | HonorHealth Research Institute | 9 | 2019-12-13 | 2026-05-26 |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine Safety Laboratories, AE Assessment, Physical Exam - Metastatic Pancreatic Cancer | Phase 2 | Terminated | HonorHealth Research Institute | 1 | 2019-10-17 | 2023-10-18 |
| Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients N-Acetyl cysteine - Traumatic Brain Injury | Phase 2 | Completed | HonorHealth Research Institute | 92 | 2019-09-01 | 2026-05-01 |
| Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma NabCG (nab-Paclitaxel + Cisplatin + Gemcitabine) - Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 42 | 2019-07-15 | 2026-04-23 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer Ascorbic Acid, Paclitaxel protein-bound, Cisplatin - Metastatic Pancreatic Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Hitendra Patel | 2019-06-01 | 2019-06-11 | |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer Ascorbic Acid, Paclitaxel protein-bound, Cisplatin - Metastatic Pancreatic Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Medical College of Wisconsin | 2019-05-01 | 2019-05-30 | |
| SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy Dual Antiplatelet (DAPT) Therapy, The Synergy® stent - Coronary Artery Disease, Atherosclerosis | Phase 2 | Terminated | HonorHealth Research Institute | 50 | 2018-11-19 | 2024-12-27 |
| Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns Skylife, Standard Therapy - Jaundice, Neonatal, Neonatal Hyperbilirubinemia | Not applicable | Completed | HonorHealth Research Institute | 72 | 2018-04-15 | 2021-05-27 |
Showing 20 of 27. Sign in to see all of them.
Pancreatic Neoplasms (7) · Neoplasms (2) · Adenocarcinoma (1) · Adenomatous Polyposis Coli (1) · Alopecia (1) · Atherosclerosis (1) · Brain Injuries, Traumatic (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Colorectal Neoplasms (1) · Coronary Artery Disease (1) · Emotional Regulation (1) · Endometrial Neoplasms (1) · Hyperalgesia (1) · Hyperbilirubinemia, Neonatal (1)
Gemcitabine (10) · Cisplatin (9) · Taxes (6) · Albumin-Bound Paclitaxel (4) · Ascorbic Acid (3) · paricalcitol (3) · 130-nm albumin-bound paclitaxel (2) · Nivolumab (2) · 2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine (1) · Acetylcysteine (1) · Atovaquone (1) · Azithromycin (1) · Celecoxib (1) · Chloroquine (1) · Clinical Protocols (1)
United States (26)
Erkut Borazanci, MD (7) · Gayle Jameson, ACNP-BC (2) · Amy Mirabella, PhD, RN, CHPN (1) · Ben George, MD (1) · David Rizik, MD (1) · Donald B Penzien, PhD (1) · Erkut Borazanci, MD, MS (1) · Gayle Jameson (1) · Gayle S Jameson, RN, MSN, ACNP-BC, AOCN (1) · Hitendra Patel, MD (1) · Jill Rau, MD, PhD (1) · Justin Moser, MD (1) · Matthew Abrams, MD (1) · Michael Gordon, MD (1) · Nadine Tung, MD (1)
PMID 35393384, PMID 37522330, PMID 39436905, PMID 41197185, PMID 41766762, PMID 42268676